{"id":54276,"date":"2026-01-15T22:30:14","date_gmt":"2026-01-15T14:30:14","guid":{"rendered":"https:\/\/flcube.com\/?p=54276"},"modified":"2026-05-08T14:58:35","modified_gmt":"2026-05-08T06:58:35","slug":"wuxi-biologics-licenses-clinical-stage-t-cell-engager-to-zai-lab-for-solid-tumor-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54276","title":{"rendered":"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development"},"content":{"rendered":"\n<p><strong>WuXi Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2269:HKG\">HKG:\u202f2269<\/a>) announced a licensing agreement granting <strong>Zai Lab Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZLAB:NASDAQ\">NASDAQ:\u202fZLAB<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9688:HKG\">HKG:\u202f9688<\/a>) <strong>global exclusive rights<\/strong> to develop and commercialize an <strong>innovative T\u2011cell engager (TCE)<\/strong> discovered using WuXi Bio\u2019s proprietary <strong>CD3 technology platform<\/strong> for the treatment of <strong>solid tumor indications<\/strong>. The asset has already entered clinical development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>WuXi Biologics (HKEX:\u202f2269)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Zai Lab Ltd. (NASDAQ:\u202fZLAB; HKEX:\u202f9688)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>T\u2011cell engager (TCE)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>WuXi Bio\u2019s proprietary CD3 platform<\/td><\/tr><tr><td><strong>Stage<\/strong><\/td><td>Clinical stage<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Global exclusive development and commercialization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Solid tumors<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + development, regulatory, and sales milestones + royalties + sublicense payments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>T\u2011cell engager (TCE)<\/strong> that binds <strong>CD3 on T\u2011cells<\/strong> and a tumor\u2011associated antigen on cancer cells, redirecting immune cells to eliminate solid tumors<\/li>\n\n\n\n<li><strong>Discovery Platform:<\/strong> Developed using WuXi Biologics\u2019 proprietary <strong>CD3 technology platform<\/strong>, which enables <strong>high\u2011affinity, low\u2011toxicity<\/strong> TCE design<\/li>\n\n\n\n<li><strong>Clinical Stage:<\/strong> Already entered <strong>Phase\u202fI clinical trials<\/strong>; safety and preliminary efficacy data expected <strong>Q2\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Addresses the <strong>challenging solid tumor microenvironment<\/strong> with a <strong>differentiated CD3 binders<\/strong> designed to minimize cytokine release syndrome (CRS)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Solid Tumor Patients (Annual)<\/strong><\/td><td>4.2\u202fmillion<\/td><td>18.5\u202fmillion<\/td><\/tr><tr><td><strong>TCE\u2011Eligible Population (2030E)<\/strong><\/td><td>1.8\u202fmillion<\/td><td>8.2\u202fmillion<\/td><\/tr><tr><td><strong>TCE Market (2030E)<\/strong><\/td><td>\u00a512\u202fbillion<\/td><td>$8.5\u202fbillion<\/td><\/tr><tr><td><strong>Current TCE Penetration<\/strong><\/td><td>&lt;2\u202f%<\/td><td>&lt;3\u202f%<\/td><\/tr><tr><td><strong>WuXi Bio TCE Revenue (2030E)<\/strong><\/td><td>\u2013<\/td><td>$450\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Amgen<\/strong> \u2013 BiTE platform (blinatumomab for leukemia; solid tumor programs in Phase\u202fII)<\/li>\n\n\n\n<li><strong>Roche<\/strong> \u2013 CEA\u2011CD3 TCE (RG6120) in Phase\u202fII for colorectal cancer<\/li>\n\n\n\n<li><strong>Janssen<\/strong> \u2013 GPRC5D\u2011CD3 TCE (talquetamab) approved for myeloma; solid tumor programs pre\u2011clinical<\/li>\n\n\n\n<li><strong>Zai Lab + WuXi Bio<\/strong> \u2013 <strong>First proprietary CD3 platform TCE<\/strong> for solid tumors with <strong>global rights<\/strong>; differentiated safety profile<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For WuXi Biologics:<\/strong><\/li>\n\n\n\n<li><strong>Validates discovery platform:<\/strong> First clinical\u2011stage TCE from proprietary CD3 platform licensed to a global partner<\/li>\n\n\n\n<li><strong>Revenue diversification:<\/strong> Upfront payment plus milestones and royalties provide <strong>non\u2011dilutive funding<\/strong> for platform expansion<\/li>\n\n\n\n<li><strong>CRDMO synergy:<\/strong> Zai Lab will leverage WuXi Bio\u2019s manufacturing capabilities for clinical and commercial supply<\/li>\n\n\n\n<li><strong>For Zai Lab:<\/strong><\/li>\n\n\n\n<li><strong>Clinical\u2011stage asset:<\/strong> Adds a <strong>Phase\u202fI\u2011ready TCE<\/strong> to its oncology pipeline, expanding beyond ADCs and checkpoint inhibitors<\/li>\n\n\n\n<li><strong>Global footprint:<\/strong> Leverages Zai Lab\u2019s <strong>China commercial strength<\/strong> and <strong>global development expertise<\/strong> to advance the TCE worldwide<\/li>\n\n\n\n<li><strong>Solid tumor focus:<\/strong> Addresses high\u2011unmet\u2011need indications like <strong>colorectal, gastric, and pancreatic cancer<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for the TCE asset. Actual results may differ due to clinical trial outcomes, competitive dynamics, and partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>WuXi Biologics (HKG:\u202f2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ:\u202fZLAB, HKG:\u202f9688) global exclusive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,19,952,869,868,292,413],"class_list":["post-54276","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-cro-cmo-cdmo","tag-hkg-2269","tag-hkg-9688","tag-nasdaq-zlab","tag-wuxi-biologics","tag-zai-lab"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi Biologics (HKG:\u202f2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ:\u202fZLAB, HKG:\u202f9688) global exclusive rights to develop and commercialize an innovative T\u2011cell engager (TCE) discovered using WuXi Bio\u2019s proprietary CD3 technology platform for the treatment of solid tumor indications. The asset has already entered clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54276\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development\" \/>\n<meta property=\"og:description\" content=\"WuXi Biologics (HKG:\u202f2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ:\u202fZLAB, HKG:\u202f9688) global exclusive rights to develop and commercialize an innovative T\u2011cell engager (TCE) discovered using WuXi Bio\u2019s proprietary CD3 technology platform for the treatment of solid tumor indications. The asset has already entered clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54276\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T14:30:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T06:58:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54276#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54276\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development\",\"datePublished\":\"2026-01-15T14:30:14+00:00\",\"dateModified\":\"2026-05-08T06:58:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54276\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 2269\",\"HKG: 9688\",\"NASDAQ: ZLAB\",\"WuXi Biologics\",\"Zai Lab\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54276#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54276\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54276\",\"name\":\"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-15T14:30:14+00:00\",\"dateModified\":\"2026-05-08T06:58:35+00:00\",\"description\":\"WuXi Biologics (HKG:\u202f2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ:\u202fZLAB, HKG:\u202f9688) global exclusive rights to develop and commercialize an innovative T\u2011cell engager (TCE) discovered using WuXi Bio\u2019s proprietary CD3 technology platform for the treatment of solid tumor indications. The asset has already entered clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54276#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54276\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54276#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development - Insight, China&#039;s Pharmaceutical Industry","description":"WuXi Biologics (HKG:\u202f2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ:\u202fZLAB, HKG:\u202f9688) global exclusive rights to develop and commercialize an innovative T\u2011cell engager (TCE) discovered using WuXi Bio\u2019s proprietary CD3 technology platform for the treatment of solid tumor indications. The asset has already entered clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54276","og_locale":"en_US","og_type":"article","og_title":"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development","og_description":"WuXi Biologics (HKG:\u202f2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ:\u202fZLAB, HKG:\u202f9688) global exclusive rights to develop and commercialize an innovative T\u2011cell engager (TCE) discovered using WuXi Bio\u2019s proprietary CD3 technology platform for the treatment of solid tumor indications. The asset has already entered clinical development.","og_url":"https:\/\/flcube.com\/?p=54276","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T14:30:14+00:00","article_modified_time":"2026-05-08T06:58:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54276#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54276"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development","datePublished":"2026-01-15T14:30:14+00:00","dateModified":"2026-05-08T06:58:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54276"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","CRO \/ CMO \/ CDMO","HKG: 2269","HKG: 9688","NASDAQ: ZLAB","WuXi Biologics","Zai Lab"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54276#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54276","url":"https:\/\/flcube.com\/?p=54276","name":"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-15T14:30:14+00:00","dateModified":"2026-05-08T06:58:35+00:00","description":"WuXi Biologics (HKG:\u202f2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ:\u202fZLAB, HKG:\u202f9688) global exclusive rights to develop and commercialize an innovative T\u2011cell engager (TCE) discovered using WuXi Bio\u2019s proprietary CD3 technology platform for the treatment of solid tumor indications. The asset has already entered clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54276#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54276"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54276#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi Biologics Licenses Clinical\u2011Stage T\u2011Cell Engager to Zai Lab for Solid Tumor Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54276"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54276\/revisions"}],"predecessor-version":[{"id":54277,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54276\/revisions\/54277"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}